Join Next LSI Event

Join Now

LSI Europe '24 Summit

Filling Fast

Yoel Ezra, EFA Technologies - Fully Automated Diagnostic System | LSI Europe '22

Speakers

Yoel Ezra

Yoel Ezra

CEO & Founder, eFa Technologies
Read Biography
EFA developed RevDx™, a revolutionary, CE-approved, mobile, and fully automated diagnostic system for the point of care, including primary care physicians, home-care, emergency, and remote locations. A very easy-to-use process from a finger prick to results in a few minutes. The first application is the Complete Blood Count test and more to follow

Transcription

Yoel Ezra  0:11  

Okay, hello. So, in my previous life, I, sir, I've been in in different worlds, I served for 24 years in this way the army, I've been the chief commander for technical operation unit, mainly for special operation. And when I retired, I decided to move to the medical devices. So it's a different world, but with a lot of similarities. And I got lucky enough to start working with Medtronic and Edward Life Sciences instructional health project, before I decided to go to my journey with the vision to bring medical technology accessible to everyone, and that is Efa engineering for so we are focusing first on bringing the lab test to be accessible, the essential left is to be accessible to everyone everywhere, to streamline the patient journey, to show to the time from hours, days to minutes, and to excel to extend the capabilities from the lab, to the community level. So that at that matter, we will be able to have early diagnostic, rapid diagnostic, a much appropriate treatment, and much better user experience. And of course, to save time and money, which is important in this in this area. So our solution is how we develop the Rev DX, the Rev DX platform, what you see over here, it's actually it's exciting because it's the first time we are taking it out of the borders of Israel. So it's a fully automated portable device, focusing on the essential dermatologic test. And we challenge the three aspects of accessibility, very highly and mobile and mobile solution battery operated, no need for connectivity to electricity, or the internet, very easy to use some like a glucometer and affordable and most important, it's a platform for new application. So same like a microscope when you bring different experts. That's the way we build it. So as mentioned, we are focusing on the most essential hematology lab tests, which is the complete blood count, every physician knows what to do B complete that count, for immune system for anemia, for other blood malignant malignant NF. And, but it's not only for that, we plan for additional tests in our roadmap for inflammatory indications, metabolic tests and more. So once a rev deck solution will be in the market, we will be able to collect more and more valuable information for decision makers. And we are focusing on the following use cases. So especially with fever, like you know your child, yourself, aiming to reduce as we can, the unnecessary use of antibiotic for example, and more anemia screening at the emergency setting, early detection of bleeding and infection and for chronic patients at home to have the comfort comfortable monitoring their home. So how it works. So first we have from the fingerprick, we have the disposable microfluidic and based a what we call test cheap, very simple to manufacture. But with a lot of charging challenges is inside we have several patents on it. So all you need to do to do a finger prick, put it inside, get the blood capillary force into the channels. And that's it from the user experience there. The next step is putting into this beautiful baby. And everything is automatically so this high complex platform, it's a very easy to use device. So all you need to do to put inside and that's it from the user, everything is automatically the third layer is the hybrid algorithm what we call the hybrid algorithm, it spectrum analysis, image processing, and machine learning for the morphology. So at the end, you will get the results on the screen on the device, you can treat it you can share it of course or you can connect it to the EMR. The business model is quite straightforward. Once you have the device, the revenue is coming from the disposable. Same like your razor razor blade, same like the Nespresso and of course, the idea behind the platform is that when you have new application, and this is our plan, you only need to do to download and upgrade the device. You don't need to replace the device same luck in your smartphone. So we are not saying we are doing all the lab tests. We are focusing first on the complete blood count, which is a big market by himself and extending the lab capabilities to the community level and looking at the highly growing point of care market which everyone knows accelerated from the COVID-19 pandemic. And the go to market strategy is really looking at at the community level. So the primary care In the GPS, the family office, the pediatrician, this one is for the pediatrician. We have different colors for others, the home care, and of course the walk in clinic. So these are the first markers that we are looking at. But there are others very interesting market that we are looking at at a second stage, even the veterinary market, which is a huge market by itself. Now, if you're looking to add a solution in this area, there are several solutions, not too many in this in this space specifically, for complete blood count with all the five differential. There are desktop solutions. So most of them it's desktop like like a desktop computer or printer. Some of them you need to calibrate when you move it from one place to another. In our case, all the focus was accessibility, no need for calibration. I mean, you can take it put it, it's not sensitive, although there is a high robotic microscope inside. It's a single step use a very easy to use process. And it's a platform for new application. So this is what we believe are advantages to the other solutions. We started our journey about beginning of 2019. So after about three and a half years, we have our first MVP ready and approved our first version approved, we are working on improvements, we are preparing our production line for the disposable and the end the devices. We already signed the first distributor agreement. And we have three families of patents. In pending in 10 countries, one of them already approved in the US one of the other one in Japan, and more to follow. And of course what we are most probably is the team. So we have a very talented team very diverse team. years of experience in management, business development, marketing, PhDs in the bioengineering physic algorithm and young engineers in multidisciplinary areas. Together with our advisory board, we have Professor over a Nobel Prize Laureate in the field of chemistry and medicine. Dr. Stein, he was 20 years chief of science in Mobileye, maybe some of you are familiar with Mobileye as a lot of patents in this area of imaging and algorithm, and physicians from the public sector expert in infectious diseases, and internal medicine and family practitioners. So we are actually in the A Round, already close to $3.6 million from existing existing and new investors and we are looking for around eight to $10 million dollars to close the round. Looking also for strategic partners, we already are in long term connection with leading corporates in this area, and of course, distributors. So our goals is moving to the next step of commercialization, first of all Europe. And we have the see, and we plan to go maybe also to the ivdr next year, and then following the US market after the dual submission for the 510 K CLIA waiver. And this is one of the advantages this system can be clear with it and they are not so much like this in the market. So we are starting with the CDC like mentioned, but more application will be developed on the same platform. So really, our vision is simple. And we aim to bring out our solution accessible and available in every place in the world, whether in the UK, Europe, US or in other corners of the world. So like everyone else if you want to save life and improve quality of life. Thank you very much.

 

LSI USA '24 is filling fast. Secure your spot today to join Medtech and Healthtech leaders in Dana Point.

JOIN US TODAY

Share this video

Companies We Work With